|
| |
Dow Pharmaceutical SciencesDow Pharmaceutical Sciences creates and develops superior topical products for our clients. Our vision is to be the best topical product development company in the world. Since 1977 we have built Dow into a full-scope topical product development company. We can design, develop and optimize your topical formulation, utilizing skin penetration studies from our Skin Biology Laboratory. We provide analytical method development and validation, stability testing, clinical materials manufacturing, and labeling and distribution of your clinical trial materials.To meet your dermatology needs, we provide expert staff within regulatory, clinical affairs and dermatology clinical trial sites to conduct the regulatory planning and filings as well as the Non-clinical and clinical testing needed to take your product through NDA approval. We like to say that Dow Pharmaceutical Sciences is the D in topicals R & D. Whether you need modular or “full-scope” services, please give us a call to discuss you specific needs
| Contact Details: |
| 1330A Redwood Way |
| Petaluma |
| California |
| 94954-1169 |
| United States of America |
| Tel: | 707.793.2600 |
| Fax: | 707.793.0145 |
| Email: | dosborne@dowpharmsci.com |
| WWW: | www.dowpharm.com/
|
|
Loading...
|
Recent Publications by Dow Pharmaceutical Sciences: |  |
The development and optimization of a fixed combination of clindamycin and benzoyl peroxide aqueous gel.
Fixed combination products of clindamycin 1% (as 1.2% clindamycin... | 29th July, 2009
| Dow Pharmaceutical Sciences, Inc., Petaluma, CA 94954-7121, USA.
| J Drugs Dermatol. 2009 Jul;8(7):634-8.
|
Development of a gel permeation chromatographic assay to achieve mass balance in cellulose acetate phthalate stability studies.
Cellulose acetate phthalate (CAP, cellulose acetate... | 1st May, 2009
| Dow Pharmaceutical Sciences, Inc., 1330 Redwood Way, Petaluma, CA 94954,
| J Pharm Biomed Anal. 2009 Feb 20;49(2):240-6. Epub 2008 Nov 5.
DOI Direct Link |
A novel aqueous metronidazole 1% gel with hydrosolubilizing agents (HSA-3).
Rosacea is a common chronic dermatosis that often is characterized by the... | 6th June, 2006
| Dow Pharmaceutical Sciences, Petaluma, California, USA.
| Cutis. 2006 Apr;77(4 Suppl):18-26.
|
A look at the safety of metronidazole 1% gel: cumulative irritation, contact sensitization, phototoxicity, and photoallergy potential.
Rosacea is a common, recurrent, inflammatory dermatologic disorder... | 6th June, 2006
| Solano Clinical Research, Dow Pharmaceutical Sciences, Petaluma,
| Cutis. 2006 Apr;77(4 Suppl):12-7.
|
Press Releases on Dow Pharmaceutical Sciences:
|
 |
| Valeant Buys-Out Rights to All Current and Future Income and Milestone Obligations From Former Dow Stockholders |
29th September, 2009 |
Valeant Pharmaceuticals International |
ALISO VIEJO, Calif., Sept. 29 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals International (NYSE: VRX) today announced that, for a one-time payment of $115 million, it has agreed to buy-out income
|
| Valeant Pharmaceuticals Reports First Quarter Financial Results |
5th May, 2009 |
Valeant Pharmaceuticals International |
- Revenue up 17%, 36% at constant exchange rates
- GAAP EPS $0.37, adjusted Cash EPS $0.46
- Cash Flow from operations $51 million
- Increased guidance for 2009, Cash EPS to $1.70 - 1.90
ALISO
|
| 'Topical Dermatological Product Development in the USA' Workshop to Be Held on June 4, 2009 in East Brunswick, New Jersey, USA |
9th April, 2009 |
|
PETALUMA, California, April 9 /PRNewswire/ -- Dow Pharmaceutical Sciences, Inc. today announced that it will hold a
1-day workshop on "Topical Dermatological Product Development in the USA"
|
| Valeant Pharmaceuticals Appoints President of Valeant Pharmaceuticals International |
19th March, 2009 |
Valeant Pharmaceuticals International |
ALISO VIEJO, Calif., March 19 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals (NYSE: VRX) today announced that it has appointed Dr. Bhaskar Chaudhuri to the position of President, Valeant
|
| Valeant Pharmaceuticals Reports Fourth Quarter and Full Year Financial Results |
24th February, 2009 |
Valeant Pharmaceuticals International |
ALISO VIEJO, Calif., Feb. 24 /PRNewswire-FirstCall/ -- Valeant
Pharmaceuticals International (NYSE: VRX) today announced fourth quarter and
full year financial results for 2008.
"With
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 594 times since April 2007, the link to the organisation's website has been followed 59 times Recent Search Terms used to find this page: news results for dow pharmaceuticals | dow pharmaceutical sciences | dow pharmaceutical sciences idp 107 | dow pharmaceutical sciences revenue | valeant dow pharm pdf | Dow Sciences | dow pharmaceutical financials | dow pharmaceutical sciences | CAP Dow Pharmaceutical science | 2009 revenues dowpharmaceuticals valeant | . Search for more companies in Petaluma Search for more companies in California This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Dow Pharmaceutical Sciences |
